Viridian Therapeutics Appoints New CMO, Elects Director
Ticker: VRDN · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1590750
Sentiment: neutral
Topics: leadership-change, board-election, executive-appointment
TL;DR
Viridian Therapeutics brings in a new CMO and adds a director to the board.
AI Summary
Viridian Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers. This filing follows a period of significant corporate changes, including a name change from Miragen Therapeutics, Inc. in 2017.
Why It Matters
The appointment of a new Chief Medical Officer and the addition of a new director can signal strategic shifts in the company's research and development or governance, potentially impacting future drug development and business strategy.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts that may affect the company's strategic direction and operational execution.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
FAQ
Who has been appointed as the new Chief Medical Officer for Viridian Therapeutics?
Dr. Jonathan G. Drachman has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors at Viridian Therapeutics?
Ms. Sarah E. Kelly has been elected to the Board of Directors.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported is June 17, 2024.
What was Viridian Therapeutics previously known as?
Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
What items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 747 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-06-20 16:16:55
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d857947d8k.htm (8-K) — 38KB
- d857947dex101.htm (EX-10.1) — 188KB
- g857947g0620161501854.jpg (GRAPHIC) — 3KB
- 0001193125-24-164461.txt ( ) — 392KB
- vrdn-20240617.xsd (EX-101.SCH) — 3KB
- vrdn-20240617_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240617_pre.xml (EX-101.PRE) — 11KB
- d857947d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 10.1 Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: June 20, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director